Niagen Bioscience (NAGE) said Monday that it does not expect global tariffs to disrupt its ability to manufacture food- and pharmaceutical-grade Niagen products, nor will they have an adverse impact on its ability to maintain costs and pricing.

The company said all of its vitamins and food supplements are manufactured in the US by privately held specialty chemicals company WR Grace and are tested, bottled and packaged domestically. It also said only a small percentage of its raw materials are sourced internationally, which keeps costs relatively stable in the face of global price volatility.

Foreign sales accounted for 24% of Niagen's revenue last year, with half of that coming from AS Watson in Hong Kong, which remains a duty-free market, the company said.

Niagen chief executive officer Rob Fried said the company had previously decided to establish a US-based supply chain to ensure long-term resilience and quality.

Niagen shares were more than 6% lower soon after Monday's opening bell.

Price: 5.64, Change: -0.38, Percent Change: -6.23